Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Affimed N.V. - Common Stock (NQ:AFMD)

0.0998 -0.0302 (-23.23%)
Streaming Delayed Price Updated: 11:26 AM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,575,009
Open 0.1050
Bid (Size) 0.0980 (21)
Ask (Size) 0.0999 (18)
Prev. Close 0.1300
Today's Range 0.0969 - 0.1071
52wk Range 0.1010 - 8.950
Shares Outstanding 15,227,463
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top movers in Thursday's pre-market session
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
Wednesday's pre-market session: top gainers and losers
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill

Performance

YTD
-92.6%
-92.6%
1 Month
-87.4%
-87.4%
3 Month
-90.0%
-90.0%
6 Month
-97.3%
-97.3%
1 Year
-98.1%
-98.1%

More News

Read More
Affimed Announces Receipt of Nasdaq Delisting Notice
From Affimed N.V.
Via GlobeNewswire
A Look Ahead: Affimed's Earnings Forecast
Via Benzinga
These stocks are moving in today's session
Via Chartmill
Crude Oil Gains 3%; US Inflation Eases In April
Via Benzinga
Topics Economy
Exposures Fossil Fuels Interest Rates
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales
Via Benzinga
This Caterpillar Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Affimed Announces Filing for the Opening of Insolvency Proceedings
From Affimed N.V.
Via GlobeNewswire
This Rapid7 Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday
Via Benzinga
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed Receives Nasdaq Deficiency Notice Over Low Share Price: Retail’s In Wait-And-Wait Mode
Via Stocktwits
Topics World Trade
Exposures Tariff
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
From Affimed N.V.
Via GlobeNewswire
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
From Affimed N.V.
Via GlobeNewswire
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
From Affimed N.V.
Via GlobeNewswire
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
From Affimed N.V.
Via GlobeNewswire
Affimed Reports Third Quarter 2024 Financial Results & Business Update
From Affimed N.V.
Via GlobeNewswire
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
From Affimed N.V.
Via GlobeNewswire
Earnings Scheduled For November 14, 2024
Via Benzinga

Frequently Asked Questions

Is Affimed N.V. - Common Stock publicly traded?
Yes, Affimed N.V. - Common Stock is publicly traded.
What exchange does Affimed N.V. - Common Stock trade on?
Affimed N.V. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Affimed N.V. - Common Stock?
The ticker symbol for Affimed N.V. - Common Stock is AFMD on the Nasdaq Stock Market
What is the current price of Affimed N.V. - Common Stock?
The current price of Affimed N.V. - Common Stock is 0.0998
When was Affimed N.V. - Common Stock last traded?
The last trade of Affimed N.V. - Common Stock was at 05/15/25 11:26 AM ET
What is the market capitalization of Affimed N.V. - Common Stock?
The market capitalization of Affimed N.V. - Common Stock is 1.52M
How many shares of Affimed N.V. - Common Stock are outstanding?
Affimed N.V. - Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.